Wael Al Mahmeed1
Khalid Al-Rasadi2
Yajnavalka Banerjee3Antonio Ceriello4Francesco Cosentino5
Massimo Galia6
Su-Yen Goh7
Peter Kempler8
Nader Lessan9
Nikolaos Papanas10
Ali A. Rizvi11,12Raul D. Santos13,14
Anca P. Stoian15
Peter P. Toth16
Manfredi Rizzo12,15,17* and The CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO)- 1Cleveland Clinic, Heart and Vascular Institute, Abu Dhabi, United Arab Emirates
- 2Medical Research Center, Sultan Qaboos University, Muscat, Oman
- 3Department of Biochemistry, Mohamed Bin Rashid University, Dubai, United Arab Emirates
- 4IRCCS MultiMedica, Milan, Italy
- 5Unit of Cardiology, Karolinska Institute and Karolinska University Hospital, University of Stockholm, Stockholm, Sweden
- 6Department of Biomedicine, Neurosciences and Advanced Diagnostics (Bind), University of Palermo, Palermo, Italy
- 7Department of Endocrinology, Singapore General Hospital, Singapore, Singapore
- 8Department of Medicine and Oncology, Semmelweis University, Budapest, Hungary
- 9Imperial College London Diabetes Centre, The Research Institute, Abu Dhabi, United Arab Emirates
- 10Second Department of Internal Medicine, Diabetes Center, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
- 11Department of Medicine, University of Central Florida College of Medicine, Orlando, FL, United States
- 12Division of Endocrinology, Diabetes and Metabolism, University of South Carolina School of Medicine, Columbia, IN, United States
- 13Heart Institute (InCor) University of Sáo Paulo Medical School Hospital, Sáo Paulo, Brazil
- 14Hospital Israelita Albert Einstein, Sáo Paulo, Brazil
- 15Faculty of Medicine, Diabetes, Nutrition and Metabolic Diseases, Carol Davila University, Bucharest, Romania
- 16Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, United States
- 17Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Palermo, Italy
Efforts in the fight against COVID-19 are achieving success in many parts of the world, although progress remains slow in other regions. We believe that a syndemic approach needs to be adopted to address this pandemic given the strong apparent interplay between COVID-19, its related complications, and the socio-structural environment. We have assembled an international, multidisciplinary group of researchers and clinical practitioners to promote a novel syndemic approach to COVID-19: the CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO). This geographically diverse group aims to facilitate collaborative-networking and scientific exchanges between researchers and clinicians facing a multitude of challenges on different continents during the pandemic. In the present article we present our “manifesto”, with the intent to provide evidence-based guidance to the global medical and scientific community for better management of patients both during and after the current pandemic.
Introduction
There is a bidirectional pathophysiologic relationship between coronavirus disease 2019 (COVID-19) and cardiometabolic diseases, and individuals at risk of the latter require careful consideration as the global pandemic continues to take its toll. Diabetes, obesity, and cardiovascular disease are associated with an increased risk for severe forms of COVID-19 and resulting death (1–6). At the same time, patients with COVID-19 infection are more prone to the development of new-onset diabetes mellitus (7). Investigators from different areas have emphasized the clinical relevance of the increased incidence of diabetes after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (8, 9). Furthermore, COVID-19 is associated with cardiovascular injury attributed to heightened inflammation, endothelial dysfunction and microthrombi formation (10–13). Endothelial dysfunction plays an important role in the pathogenesis of COVID-19, particularly in patients with pre-existing hypertension, diabetes, obesity and cardiovascular diseases (14). The endothelium, and particularly pulmonary endothelium, seems to be a key target organ in COVID-19 patients and its dysfunction has been shown to cause an impaired organ perfusion that can generate acute myocardial injury, renal failure, and a procoagulant state resulting in thromboembolic events (14–16).
It has been shown that SARS-CoV-2 can induce several pro-inflammatory cytokines (17) and that patients with severe COVID-19 develop a “cytokine storm syndrome” (18). Since these first observations it is become clear that the same cytokines that induce aberrant endothelial function may also trigger the acute phase response, which, in combination with local endothelial dysfunction, can lead to clinical consequences (14); indeed, inflammatory cytokines have a major role in both diabetes and cardiovascular diseases (19). Other authors have shown that COVID-19 is associated with myocardial damage such as myocarditis, arrhythmia and reduced left ventricular ejection fraction (20), all of which are associated to increased mortality risk (21). Plasma cardiac biomarkers, such as high sensitivity troponin, creatine kinase and N-terminal pro-B-type natriuretic peptide, are also associated with COVID-19 severity in adults and children (22, 23).
Beyond the direct effect of COVID-19 on the cardiovascular system and metabolic homeostasis, subjects with pre-existing cardiometabolic issues appear to be at a significantly higher risk of complications owing to reduced physical activity, altered eating behaviors, and lack of access to healthcare (24). This encapsulates the so-called “indirect” impact of COVID-19 and indeed a higher incidence of cardiovascular complications and fatalities has been documented secondary to the pandemic, for example in Italy (25). Even in New York City, emergency calls for cardiac arrests rose exponentially in the weeks when COVID-19 infections approached their zenith (26). Beyond deaths attributed directly to COVID-19, a large contribution to the excess mortality reported (27) is attributable to the indirect factors, including the disruption of the proper management of many clinical conditions–including cardiometabolic diseases–by the rapid conversion of entire hospitals or clinical units to deliver COVID-19-specific care (28).
This situation has been exacerbated in some geographical areas by increased unemployment, economic collapse, and widespread poverty (29). Indeed, increasing socio-economic disparities have come to the forefront in many populations during the pandemic, rendering people more vulnerable to economic, nutritional, social, and medical insecurity, particularly during prolonged periods of necessary government-imposed restrictions or lockdowns (30). In addition, the spread of the virus and the related complications and fatalities have been facilitated among subjects with the poorest socio-economic conditions and those living in overcrowded areas (29–31). Socio-economic inequalities are of increasing relevance during the ongoing vaccination campaigns as they contribute to disparities in care across different ethnic populations and geographical areas (32).
Importance of a Syndemic Approach
The enormous efforts by many different organizations and individuals involved in the fight against COVID-19 have had some success in many parts of the world. However, this has not been universal and progress has been slow in many other regions. We believe that a syndemic approach needs to be adopted for addressing this pandemic (33) given the strong apparent interplay between COVID-19, its related complications, and the socio-structural environment. The term syndemic (from ancient Greek: syn, together; demos, people) emphasizes the relevance of biological, social, economic, and environmental factors in the health of individuals and populations (29). Physicians have an obligation to understand their patients' social, economic, and environmental situations and to utilize the tools available in existing health systems to improve their access to care. It is also expected that many health systems will continue to be under significant economic pressure, which may contribute to a reduced quality of care for patients with chronic conditions.
Another challenge is represented by the so-called long-COVID syndrome, which is a clinical condition present in subjects who have either recovered from COVID-19 but still report lasting effects of the infection or have had the usual symptoms for far longer than would be expected (34). Of increasing current interest are the neurological and neuropsychiatric complications (35), since several studies have reported a broad spectrum of symptoms, from the milder manifestations of memory loss, sleep disorders and impaired concentration to more serious cognitive decline, major depression or persistent delirium (36). Thus, there is an urgent need to better understand the long-term effects of COVID-19 on brain function, behavior and cognition. As a component of a holistic approach to the management of patients with COVID-19, mental health assessment should be included.
Capisco: An International, Multidisciplinary Collaboration
We believe it is crucial to improve interactions between specialists working in different disciplines, since insufficient cooperation has contributed to the indirect impact of COVID-19 (37). Furthermore, the pandemic has adversely medical education in many ways, for example owing to shifts to distance-learning modalities and decline in clinical clerkship due to the cancelation of routine patient appointments and surgical procedures and a transition to greater use of telemedicine (38). In response to these challenges we have recently assembled the Cardiometabolic Panel of International Experts on Syndemic COVID-19 (CAPISCO), a group of international researchers and clinical practitioners from many different disciplines including (but not limited to) diabetology, endocrinology, cardiology, lipidology, internal medicine, radiology, preventive medicine, public health and biochemistry–providing a multi-disciplinary representation in a novel approach to COVID-19 (Figure 1). We also emphasized geographical diversity when convening the group in order to facilitate collaborative-networking and scientific exchanges between researchers and clinicians facing a multitude of challenges in different continents during the pandemic.
Figure 1. A novel multi-disciplinary syndemic approach to cardiometabolic diseases during COVID-19.
Members of CAPISCO intend to collaboratively investigate:
1. how patients with cardiometabolic diseases and its complications are currently being managed and treated and the extent to which the pandemic impacts proper management, with a view to identifying, categorizing and defining innovative strategies to overcome potential barriers and disparities;
2. why differences in COVID-19 mortality rates have been reported among various countries, beyond the prevalence of the disease per se, with the aim to elucidate the social, economic and environmental factors potentially impacting clinical outcomes;
3. whether telemedicine is a reliable and useful tool to deliver high-quality patient care in light of experience gained during the pandemic; across different geographical areas we aim to investigate: what was successfully implemented and how, what was not successfully implemented and why, and what still needs to be improved;
4. how to assess the burden and late consequences of delayed management of cardiometabolic disease and other conditions due to COVID-19.
Ultimately, the overarching aim of CAPISCO is to give evidence-based guidance for the management of patients with cardiometabolic diseases during and after COVID-19 based on a syndemic approach. In terms of methodology, we plan to use a systematic approach, including systematic literature searches, formal quality-grading and analysis of collected studies, resulting in graded levels of recommendations. We also intend to make a roadmap plan of further research avenues once the data from the above indicated tools becomes available; this may also involve cooperation with health authorities and other international organizations.
Conclusions
In conclusion, we believe it is crucial to view COVID-19 through a syndemic lens to properly tackle the interlinked public health, medical, social and economic challenges that amplify each other in this crisis. The acronym of our expert panel, CAPISCO, is meaningful, since the word “capisco” means in Italian, “I understand”. CAPISCO contributions will promote a holistic approach for all patients with cardiometabolic diseases based on solid, validated scientific research and clinical expertise. We hope that physicians around the world will be able to use them to help benefit clinical care, follow-up, and monitoring of their patients during and after the COVID-19 pandemic.
Data Availability Statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
Author Contributions
This article is the result of three expert panel meetings conducted virtually between May and July 2021. MR and WA, co-chairs of CAPISCO, prepared the first draft of this article, which was first critically discussed and reviewed with AR, AC, and AS, and then extensively reviewed by all the other members. All authors have equally contributed to the final manuscript and are listed alphabetically.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Ceriello A, Standl E, Catrinoiu D, Itzhak B, Lalic NM, Rahelic D, et al. Issues of cardiovascular risk management in people with diabetes in the COVID-19 era. Diabetes Care. (2020) 43:1427–32. doi: 10.2337/dc20-0941
2. Khera A, Baum SJ, Gluckman TJ, Gulati M, Martin SS, Michos ED, et al. Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. Am J Prev Cardiol. (2020) 1:100009. doi: 10.1016/j.ajpc.2020.100009
3. Schnell O, Cos X, Cosentino F, Forst T, Giorgino F, Heersprink HJL, et al. Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. Cardiovasc Diabetol. (2021) 20:75. doi: 10.1186/s12933-021-01254-1
4. Atallah B, El Lababidi R, Jesse W, Noor L, AlMahmeed W. Adapting to the COVID-19 pandemic at a quaternary care hospital in the Middle East Gulf region. Heart Views. (2020) 21:133–40.
5. Ceriello A, Stoian AP, Rizzo M. COVID-19 and diabetes management: What should be considered? Diabetes Res Clin Pract. (2020) 163:108151. doi: 10.1016/j.diabres.2020.108151
6. Stoian AP, Banerjee Y, Rizvi AA, Rizzo M. Diabetes and the COVID-19 pandemic: How Insights from recent experience might guide future management. Metab Syndr Relat Disord. (2020) 18:173–75. doi: 10.1089/met.2020.0037
7. Papachristou S, Stamatiou I, Stoian AP, Papanas N. New-onset diabetes in COVID-19: Time to frame its fearful symmetry. Diabetes Ther. (2021) 12:461–4. doi: 10.1007/s13300-020-00988-7
8. Shrestha DB, Budhathoki P, Raut S, Adhikari S, Ghimire P, Thapaliya S, et al. New-onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. World J Virol. (2021) 10:275–87. doi: 10.5501/wjv.v10.i5.275
9. Mameli C, Scaramuzza A, Macedoni M, Marano G, Frontino G, Luconi E, et al. Type 1 diabetes onset in Lombardy region, Italy, during the COVID-19 pandemic: The double-wave occurrence. EClinicalMedicine. (2021) 39:101067. doi: 10.1016/j.eclinm.2021.101067
10. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. (2020) 5:1265–73. doi: 10.1001/jamacardio.2020.3557
11. Ferrari F, Martins VM, Teixeira M, Santos RD, Stein R. COVID-19 and Thromboinflammation: is there a role for statins? Clinics (Sáo Paulo). (2021) 76:e2518. doi: 10.6061/clinics/2021/e2518
12. Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. (2020) 41:3038–44. doi: 10.1093/eurheartj/ehaa623
13. Pellegrini D, Kawakami R, Guagliumi G, Sakamoto A, Kawai K, Gianatti A, et al. Microthrombi as a major cause of cardiac injury in COVID-19: a pathologic study. Circulation. (2021) 143:1031–42. doi: 10.1161/CIRCULATIONAHA.120.051828
14. Ionescu M, Stoian AP, Rizzo M, Serban D, Nuzzo D, Mazilu L, et al. The Role of Endothelium in COVID-19. Int J Mol Sci. (2021) 22:11920. doi: 10.3390/ijms222111920
15. Kaur S, Tripathi DM, Yadav A. The enigma of endothelium in COVID-19. Front Physiol. (2020) 11:989. doi: 10.3389/fphys.2020.00989
16. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med. (2020) 9:1417. doi: 10.3390/jcm9051417
17. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I. e al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. (2020) 34:327–31.
18. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. Across Speciality Collaboration, UK COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. (2020) 395:1033–4. doi: 10.1016/S0140-6736(20)30628-0
19. Abate N, Sallam HS, Rizzo M, Nikolic D, Obradovic M, Bjelogrlic P, et al. Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr Pharm Des. (2014) 20:4961–9. doi: 10.2174/1381612819666131206103102
20. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. (2020) 5:831–40. doi: 10.1001/jamacardio.2020.1286
21. Silverio A, Di Maio M, Scudiero F, Russo V, Esposito L, Attena E, et al. Clinical conditions and echocardiographic parameters associated with mortality in COVID-19. Eur J Clin Invest. (2021) 51:e13638. doi: 10.1111/eci.13638
22. Zhu Z, Wang M, Lin W, Cai Q, Zhang L, Chen D, et al. Cardiac biomarkers, cardiac injury, and comorbidities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Immun Inflamm Dis. (2021) 9:1071–100. doi: 10.1002/iid3.471
23. Zhao Y, Patel J, Huang Y, Yin L, Tang L. Cardiac markers of multisystem inflammatory syndrome in children (MIS-C) in COVID-19 patients: A meta-analysis. Am J Emerg Med. (2021) 49:62–70. doi: 10.1016/j.ajem.2021.05.044
24. Bornstein SR, Rubino F, Ludwig B, Rietzsch H, Schwarz PEH, Rodionov RN, et al. Consequences of the COVID-19 pandemic for patients with metabolic diseases. Nat Metab. (2021) 3:289–92. doi: 10.1038/s42255-021-00358-y
25. De Rosa S, Spaccarotella C, Basso C, Calabrò MP, Curcio A, Filardi PP, et al. Società Italiana di Cardiologia and the CCU Academy investigators group. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. (2020) 41:2083–8. doi: 10.1093/eurheartj/ehaa409
26. Wessler BS, Kent DM, Konstam MA. Fear of coronavirus disease 2019 – an emerging cardiac risk. JAMA Cardiol. (2020) 5:981–2. doi: 10.1001/jamacardio.2020.2890
27. Rizzo M, Foresti L, Montano N. Comparison of reported deaths from COVID-19 and increase in total mortality in Italy. JAMA Intern Med. (2020) 180:1250–2. doi: 10.1001/jamainternmed.2020.2543
28. Fadaak R, Davies JM, Blaak MJ, Conly J, Haslock J, Kenny A, et al. Rapid conversion of an in-patient hospital unit to accommodate COVID-19: An interdisciplinary human factors, ethnography, and infection prevention and control approach. PLoS ONE. (2021) 16:e0245212. doi: 10.1371/journal.pone.0245212
29. Fronteira I, Sidat M, Magalhães JP, de Barros FPC, Delgado AP, Correia T, et al. The SARS-CoV-2 pandemic: A syndemic perspective. One Health. (2021) 12:100228. doi: 10.1016/j.onehlt.2021.100228
30. Padmanabhan S. The COVID-19 pan-syndemic – will we ever learn? Clin Infect Dis. (2020) 73:e2976–7. doi: 10.1093/cid/ciaa1797
31. Available online at: https://www.nytimes.com/2021/05/04/world/oxygen-shortage-covid.html (accessed September 30th, 2021).
32. Available online at: https://www.kff.org/coronavirus-covid-19/issue-brief/latest-data-on-covid-19-vaccinationsrace-ethnicity/ (accessed September 30th, 2021).
33. Horton R. Offline: COVID-19 is not a pandemic. Lancet. (2020) 396:874. doi: 10.1016/S0140-6736(20)32000-6
34. Mahase E. Covid-19: What do we know about “long covid”? BMJ. (2020) 370:m2815. doi: 10.1136/bmj.m2815
35. Nuzzo D, Vasto S, Scalisi L, Cottone S, Cambula G, Rizzo M, et al. Post-Acute COVID-19 Neurological Syndrome: A New Medical Challenge. J Clin Med. (2021) 10:1947. doi: 10.3390/jcm10091947
36. Pantelis C, Jayaram M, Hannan AJ, Wesselingh R, Nithianantharajah J, Wannan CM, et al. Neurological, neuropsychiatric and neurodevelopmental complications of COVID-19. Aust N Z J Psychiatry. (2021) 55:750–62. doi: 10.1177/0004867420961472
37. Ceriello A. Lessons from COVID-19: How human behaviour may influence the science. Diabetes Res Clin Pract. (2020) 169:108491. doi: 10.1016/j.diabres.2020.108491
Keywords: diabetes, cardiovascular diseases, complications, COVID-19, pandemic, syndemic
Citation: Al Mahmeed W, Al-Rasadi K, Banerjee Y, Ceriello A, Cosentino F, Galia M, Goh S-Y, Kempler P, Lessan N, Papanas N, Rizvi AA, Santos RD, Stoian AP, Toth PP, Rizzo M and The CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO) (2021) Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. Front. Cardiovasc. Med. 8:787761. doi: 10.3389/fcvm.2021.787761
Received: 01 October 2021; Accepted: 22 November 2021;
Published: 15 December 2021.
Edited by:
Xiaofeng Yang, Temple University, United StatesReviewed by:
Owais Bhat, Virginia Commonwealth University, United StatesJahaira Lopez-Pastrana, Temple University, United States
Copyright © 2021 Al Mahmeed, Al-Rasadi, Banerjee, Ceriello, Cosentino, Galia, Goh, Kempler, Lessan, Papanas, Rizvi, Santos, Stoian, Toth, Rizzo and The CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO). This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Manfredi Rizzo, manfredi.rizzo@unipa.it